Peptide Injections for Weight Loss: What's in the Vial (2026)

Search "peptide injections for weight loss" and you will be shown three completely different products under one label: an FDA-approved prescription medicine, a compounded copy of that medicine prepared by a pharmacy, and an unregulated vial mailed from a website with "for research use only" on the box. They can contain nominally the same molecule. They are not the same purchase, and the differences are not paperwork — laboratory analyzes have measured what actually arrives at the door.

The short version: the injectable weight-loss peptides with real evidence are the incretin drugs, and the evidence attaches to the approved product tested in the trial, not to the molecule in the abstract. How you obtain it determines whether any of that evidence transfers. That is the argument of this page.

Before choosing a service, use our state-availability guide to check the clinician, pharmacy and exact treatment for the state where you will receive care.

The three tiers, and why the distinction is the whole story

Tier one: FDA-approved incretin drugs. Semaglutide and tirzepatide are approved, manufactured under pharmaceutical quality systems, and carry the trial data everyone quotes. In STEP 1, 1,961 adults randomized to once-weekly semaglutide 2.4 mg or placebo for 68 weeks saw mean body-weight change of −14.9% versus −2.4%¹. In SURMOUNT-1, 2,539 adults on tirzepatide reached −15.0%, −19.5% and −20.9% at 5, 10 and 15 mg against −3.1% for placebo². The investigational triple agonist retatrutide reached −24.2% at 48 weeks in phase 2, and remains unapproved³. Buying the approved drug through a telehealth platform can still separate the headline number from the real one: Wisp's "$99/month" is the consult fee for its brand-name Wegovy, Zepbound and Saxenda path — the medication itself is billed separately at pharmacy pickup or checkout, and manufacturer cash offers, dose, coverage and pharmacy choice can change that separate medication bill. That distinction between the approved-drug and compounded tiers can hide inside one storefront's own pricing, too: Kin Meds' advertised "$149/month" headline turns out to be the brand-name (Wegovy/Zepbound/Foundayo) entry price, not the compounded medication most readers expect — compounded semaglutide there actually starts at $199/month. The largest brand-name-only channels run their own version of the same gap: Amazon One Medical charges $39 for a message visit or $59 for video on its cash On-Demand weight-loss path, separately from medication and labs; the displayed $149 oral-drug starting offers depend on dose and coupon eligibility, Ro's $149/mo Foundayo figure is the drug price alone, with a recurring membership billed separately on top of it, GoodRx offers pharmacy savings for an existing prescription and a separate $39/month Care Direct service for online prescribing and follow-up; medication costs extra, and LillyDirect's cheapest advertised rate, $25/month, is closed to Medicare and Medicaid patients entirely.

Tier two: compounded versions. A licensed compounding pharmacy prepares the drug against a prescription. There is a real prescriber and a licensed pharmacy in the chain, which matters — though how much of that chain you are allowed to see varies enormously. Most sellers never name the pharmacy that fills the vial; a minority print its name and address. The range, from most to least you can check:

A named pharmacy is something you can look up with your state's board of pharmacy before you pay; a category label is not. Every GLP-1 provider we've reviewed is listed A to Z at the foot of our semaglutide ranking, and each review says whether the pharmacy is named.

Tier three: "research use only" vials sold online without a prescription. No prescriber, no pharmacy, no dispensing standard, and no obligation to make what the label claims. This is where the measured data gets ugly.

What testing actually found inside gray-market vials

This is not a hypothetical risk, and it is worth going through the numbers rather than gesturing at "quality concerns."

A 2024 purchase study selected six no-prescription online semaglutide vendors. Three orders were not delivered; three vials arrived for laboratory analysis. The JMIR and JAMA publications describe the same project⁴⁸.

• •The reported semaglutide content was 28.56%–38.69% above the label, a quantity discrepancy in those received samples⁴.
• •Table 4's 7.7%–14.37% values are semaglutide mass fractions of total powder mass, not chemical purity. They do not identify the remaining material as harmful impurities. The paper also reports no peptide-like impurities detected chromatographically⁴.
• •One endotoxin result was quantified at 8.9511 EU/mg. The other two detailed results are upper bounds, <2.8658 and <2.1645 EU/mg. The abstract's broader statement does not resolve that inconsistency; the JAMA report describes elevated endotoxin in one sample⁴⁸.
• •No viable microorganisms were detected in the three received samples. That does not establish the sterility of other vials⁸.

A separate study of 27 falsified peptide preparations found some arsenic and lead concentrations above the authors' chosen parenteral screening benchmarks. That is a concentration comparison, not a measured multiple of patient daily exposure or a clinical toxicity rate⁵.

These results justify scrutiny of labels and product traceability. A selected three-vial sample cannot establish the contents of every research vial, a market-wide failure rate or a head-to-head comparison with licensed compounded and approved medicines.

The dose arithmetic that gives false comfort

A specific failure mode is worth naming because it is so common. Someone reconstitutes a gray-market vial, works the concentration carefully, and concludes the dosing is precise.

Our semaglutide reconstitution calculator, tirzepatide reconstitution calculator and general peptide calculator convert the mass and volume entered. They cannot verify the drug identity, actual amount or sterility of a vial. In the three received semaglutide samples, the reported active amount exceeded the labels by 28.56%–38.69%⁴. A precise calculation does not validate an unverified input. The technique is explained in how to reconstitute peptides, and the diluent in our bacteriostatic water guide.

The side-effect profile that comes with the real drug

Even at tier one, these injections are not consequence-free, and the athletic corners of the internet tend to underplay it.

Gastrointestinal adverse events are the dominant tolerability issue. In STEP 1, nausea and diarrhea were the most common adverse events, and 4.5% of the semaglutide group discontinued treatment for gastrointestinal events versus 0.8% on placebo¹. A state-of-the-art safety review notes that beyond the familiar nausea, vomiting, diarrhea and constipation of dose escalation, accumulating evidence has identified further gastrointestinal complications including cholelithiasis, cholecystitis, gastroparesis and bowel obstruction⁶. A cross-sectional analysis of a large research cohort likewise found an association between GLP-1 receptor agonist use and gastrointestinal adverse events⁷ — and it is worth being precise about what a cross-sectional association can and cannot establish, which is prevalence in a population rather than causation in an individual.

None of this makes these drugs bad medicines. It makes them medicines, which is exactly the frame the "peptide injection" marketing removes.

What about the non-incretin injectables?

The other injectables marketed for weight loss are a different evidentiary category altogether, and mostly a much weaker one.

The growth-hormone fragments — AOD-9604 and HGH fragment 176-191 — are the compounds sold most explicitly as fat-loss injections, and their human program did not deliver on the promise the mechanism implied; we lay that out in the AOD-9604 evidence review and the HGH fragment 176-191 review. Tesamorelin is a genuine approved drug with randomized visceral-fat reduction, but in a specific clinical population for a specific fat depot, which we cover in tesamorelin for athletes. The GH secretagogues are sold on a lipolysis rationale that has never converted into demonstrated fat loss in healthy training people — see peptides for fat loss. And if the underlying goal is losing fat without losing muscle, the body-composition evidence is its own subject, which we work through in peptides for weight loss and muscle gain.

For anyone drug-tested, most of this category is banned in tested sport, year-round, and a prescription does not change that. Our prohibited-substance checker gives a per-compound answer rather than a rule you have to apply yourself.

The decision this page is really about

Medication selection should consider clinical eligibility, benefits, risks and cost with a licensed clinician. Product source and formulation matter too; a shared ingredient name does not make preparations interchangeable.

Approved-product trial results apply to the tested medicine. A compounded prescription is not an FDA-approved product. The small online purchase study concerned three selected no-prescription semaglutide vials; it cannot establish comparative contamination or purity across those categories⁴⁸.

The separate falsified-peptide study found some elemental concentrations above its selected screening benchmarks, not a measured patient daily-exposure multiple⁵.

If you choose a compounded prescription, read the fine print

A clean pricing page is not a regulatory record: Direct Meds publishes monthly prices alongside a displayed 90-day shipment, with the number of payments still needing confirmation, and received an FDA warning letter in September 2025 over how it marketed compounded semaglutide and tirzepatide. Before you sign up anywhere, check six things:

• •The refund line. FeelGood Meds issues no refund on cancellation after the first 72 hours, and says so in capital letters.
• •The billing unit and refill price. HeliMeds' GLP-1/GIP plan has one- and three-month offers with different first-order and refill amounts. A three-month equivalent is not a monthly debit; confirm the full payment and refill terms.
• •The commitment behind the headline. SkyRx's $199 a month requires a full 12 months paid upfront.
• •Whether one price holds across pages. Layla shows $199, $237 or $297 a month for the same compounded semaglutide, depending on which landing page you arrive on.
• •Fees outside the headline. Concierge MD LA's intake form discloses a $250 cancellation fee that the headline pricing never mentions.
• •Who actually prescribes. TelePeptide says it "does not itself practice medicine" and names its medical group only on request.

And the plain version exists: Lttl prints the cost of every commitment length up front, from $199 a month month-to-month down to $129 a month on a 12-month prepay. Every GLP-1 provider we've reviewed is listed A to Z at the foot of our semaglutide ranking, and each review works out what you'd really pay.